SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.